Cat. #160865
Tsc1iDeltaEC Tumor model for lymphangiosarcoma mouse
Cat. #: 160865
Sub-type: Mouse
Availability: 8-10 weeks
Disease: Angiosarcoma
Model: Conditional KO
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Institute: University Of Cincinnati
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Tool name: Tsc1iDeltaEC Tumor model for lymphangiosarcoma mouse
- Cancer: Sarcoma
- Cancers detailed: Angiosarcoma;Lymphangiosarcoma
- Research fields: Cancer;Drug development
- Tool sub type: Mouse
- Disease: Angiosarcoma
- Model: Conditional KO
- Conditional: Yes
- Description: Angiosarcoma/lymphangiosarcoma is a rare cancer that currently has no effective treatment. The mechanism of angiosarcoma development is largely unknown, and there is no animal model for the disease with molecularly defined pathogenesis. Loss of Tsc1 can cause hyper-activation of mTORC1 signaling in endothelial cells, which results in the development of lymphatic malformation (LM) and progression to vascular tumors that recapitulate salient features of human lymphangiosarcoma (LAS), including local invasion and systemic metastasis.
- Genetic background: Tsc1f/f mice crossed with End-Scl-Cre-ERT transgenic mice to produce Tsc1f/f;Scl-Cre mice.Â
- Zygosity: Homozygous
- Strain: C57BL/6
- Production details: Cohorts of Tsc1f/f;Scl-Cre and control littermates mice at 8-10 weeks of age were intraperitoneally injected with tamoxifen for three times (2 mg each time, every other day) to induce activation of Cre recombinase to delete floxed Tsc1 gene in endothelial cells.
- Breeding information: Exceptional breeder (8 pups per litter)
Target Details
- Target: Tsc1/Hamartin
References
- Yang et al. 2020. Br J Cancer. 122(12):1791-1802. PMID: 32336756.
- Sun et al. 2015. Cancer Cell. 28(6):758-772. PMID: 26777415.
